To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
Homeland Security bill – Pharma Immunity – WP Fri, 15 Nov 2002 The Homeland Security bill that passed the House includes sweeping last minute provisions attached to it that have nothing to do with the war on terrorism. The provisions put the interest of pharmaceutical industry giants above the health…
Bill would shield some drug firms from punitive damages Wed, 29 Dec 2004 A proposed bill in Congress would be another disincentive for pharmaceutical companies to disclose drug safety problems. Those promoting the bill should be asked to disclose their financial ties to drug companies. In 2000, a mysterious clause…
Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page:…
Member of UK Parliament Accuses Drugs Giant of ‘Voodoo Medicine’ – Scotsman Wed, 25 Feb 2004 Paul Flynn, Member of UK Parliament raised the antidepressant drug scandal in Parliament, focusing on the British drug manufacturer giant, GlaxoSmithKline (GSK). “The Seroxat [Paxil] scandal is one of gigantic proportions that affects millions…
Alabama Filed Suit against 79 Drug companies Medicaid Overcharges Sat, 29 Jan 2005 The prescription drug industry is continuing to fleece the American taxpayer – Alabama filed a lawsuit charging 79 drug companies – among them the giants, Eli Lilly, Pfizer, Brsitol-Myers, and Merck – for "intentionally" misreporting and inflating…
Marketing Drugs by Marketing Sex–Cheerleader Sales Reps Mon, 28 Nov 2005 Readers, but not the medical community, may be shocked by a front page story in The New York Times that sheds light on yet another unseemly pharmaceutical industry strategy for pushing brand name drugs. The industry’s most effective drug…
Dr. Wolpe’s Accusations and Dr. Healy’s Response —–Original Message—– From: Paul Root Wolpe Sent: Tuesday, October 28, 2003 4:30 PM To: VERACARE Subject: Re: Ethics of U Penn surgical “drug implant” experiment Vera, We will have to agree to disagree, so this will be my last email on this. A…
Follow the Money / Can the Institute of Medicine Review the FDA? Wed, 6 Apr 2005 A letter to the editor published in Nature Medicine by Dr. Bernard Carroll, a past chairman of the FDA Advisory Committee for Psychotropic Drugs, and past chairman of the Department of Psychiatry at Duke…
Cymbalta Contract: How Eli Lilly Influences What Prescribers Learn about Lilly’s drugs Fri, 5 Aug 2005 The Wall Street Journal reports that not only do drug manufacturers control what the public is told about patented drugs, but companies, such as Eli Lilly and Pfizer dictate by contract what doctors are…
AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…
Presidential Panel: Mental Health System Dysfunctional Sun, 3 Nov 2002 A panel of policy experts, convened by President Bush has issued a scathing “indictment” of the nation’s mental health care system. The Commission chair, Dr. Michael Hogan, director of the Ohio Department of Mental Health, stated: “We have trapped people…
